A Phase I Trial of the ATR inhibitor BAY 1895344 in combination with cisplatin and with cisplatin plus gemcitabine in advanced solid tumors with an emphasis on urothelial carcinoma
Study of BAY 1895344 in Combination with Chemotherapy for Patients with Advanced Cancer
Sponsor: ETCTN
Enrolling: Male and Female Patients
IRB Number: AAAT6925
U.S. Govt. ID: NCT04491942
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This study is being done to answer the following question: What is the highest dose of BAY 1895344 that can be given safely in combination with cisplatin and gemcitabine in patients with advanced solid tumors, including urothelial carcinoma? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your advanced solid tumor or urothelial carcinoma. The usual approach is defined as care most people get for advanced solid tumors or urothelial carcinoma. Cancers may include bladder cancer, breast cancer, lung cancer, gynecologic cancers, head and neck/oral cancers, and testicular cancer.
Mark Stein, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Do you have a solid tumor? Yes No
Have you previously received chemotherapy? Yes No
Are you able to make extra visits to the clinic for treatment and assessments? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator